https://www.pharmaceutical-technology.com/data-insights/celgosivir-hydrochloride-60-degrees-pharmaceuticals-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/
Celgosivir hydrochloride is under clinical development by 60 Degrees Pharmaceuticals and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections.
respiratory syncytial viruscelgosivirhydrochloridedegreespharmaceuticals